Doctors track which drug combo works better for tough lung cancers
NCT ID NCT07394062
Summary
This study aims to see which of two common treatment approaches works better for people with advanced non-small cell lung cancer that has spread and has low levels of a specific protein (PD-L1). Researchers will follow 400 patients who are already receiving one of these standard treatment combinations as part of their normal care. They will track how long patients live without their cancer getting worse, overall survival time, and how the treatments affect their quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSMALL CELL LUNG CANCER, STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Ankara Etlik City Hospital
RECRUITINGAnkara, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gazi University Faculty of Medicine, Department of Medical Oncology
RECRUITINGAnkara, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.